• LAST PRICE
    3.8000
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (0.7958%)
  • Bid / Lots
    3.7800/ 2
  • Ask / Lots
    3.8100/ 2
  • Open / Previous Close
    3.8000 / 3.7700
  • Day Range
    Low 3.7800
    High 3.9199
  • 52 Week Range
    Low 0.8600
    High 6.9800
  • Volume
    30,610
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.77
TimeVolumeGBIO
09:32 ET92353.8
09:41 ET15003.78
09:43 ET1403.8523
09:50 ET24223.87
10:01 ET1093.9199
10:03 ET2003.8756
10:06 ET3003.85
10:08 ET1123.8742
10:17 ET1023.8823
10:32 ET3003.85
10:35 ET2503.8699
10:50 ET13003.83
11:09 ET5003.815
11:38 ET5253.78
12:23 ET20033.835
12:27 ET1463.83
12:38 ET52783.8
12:39 ET1003.81
12:43 ET1003.81
12:45 ET1003.81
12:50 ET7123.795
12:54 ET1003.795
01:08 ET1003.8
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGBIO
Generation Bio Co
250.8M
-1.5x
---
United StatesIPSC
Century Therapeutics Inc
259.3M
-1.4x
---
United StatesDSGN
Design Therapeutics Inc
254.2M
-4.2x
---
United StatesPYXS
Pyxis Oncology Inc
245.5M
-3.0x
---
United StatesQSI
Quantum-Si Inc
263.7M
-2.8x
---
United StatesALDX
Aldeyra Therapeutics Inc
243.0M
-7.9x
---
As of 2024-05-17

Company Information

Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.

Contact Information

Headquarters
301 BINNEY STREETCAMBRIDGE, MA, United States 02142
Phone
857-529-5908
Fax
302-655-5049

Executives

Independent Chairman of the Board
Jason Rhodes
President, Chief Executive Officer, Director
Cameron Mcdonough
Chief Financial Officer
Matthew Norkunas
Chief Operating Officer
Antoinette Paone
Chief Scientific Officer
Matthew Stanton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$250.8M
Revenue (TTM)
$10.0M
Shares Outstanding
66.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.94
EPS
$-2.56
Book Value
$3.07
P/E Ratio
-1.5x
Price/Sales (TTM)
25.2
Price/Cash Flow (TTM)
---
Operating Margin
-1,820.04%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.